Pre-Emption Battle Looms In Supreme Court As FDA Finalizes Labeling Rule
This article was originally published in The Tan Sheet
Executive Summary
FDA's final rule on sponsors' obligations to update their labels alters the definition of "newly acquired information" from the proposed rule while leaving the remainder intact. The change could be a boon to industry, but a slap to Democrats who had called for the rule's withdrawal
You may also be interested in...
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation
Drug Industry Braces For Supreme Court Ruling In Wyeth Pre-emption Case
This week everyone's attention is riveted on the presidential election. But for the pharmaceutical industry there is another issue just as compelling. On Nov. 3, the U.S. Supreme Court will hear oral arguments in the case that will decide the future of product liability litigation